Barbara McClure

Dr. Barbara McClure

Centre for Cancer Biology, Adelaide University, Adelaide, South Australia, Australia
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2021 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
Charlotte EJ ToomesCharlotte EJ Toomes
Charlotte EJ Toomes
Barbara McClureBarbara McClure
Barbara McClure
JBJohn Bruning
John Bruning
Elyse C. PageElyse C. Page
Elyse C. Page
JBJames Breen
James Breen
Deborah L WhiteDeborah L White
Deborah L White
Ruxolitinib (rux) Phase II clinical trials are underway for the treatment of high-riskJAK2-rearranged (JAK2r) B-cell acute lymphoblastic leukemia (B-ALL). Treatment resistance to targeted inhibitors in other settings is common; elucidating potential mechanisms of rux resistance inJAK2r B-ALL will enable development of therapeutic strategies to overcome or avert resistance. We generated a murine pro-B cell model ofATF7IP-JAK2with acquired resistance to multiple type-I JAK inhibitors. Resistance was associated with mutations within theJAK2ATP/rux binding site, including aJAK2p.G993A mutation. Using in vitro models ofJAK2r B-ALL,JAK2p.G993A conferred resistance to six type-I JAK inhibitors and the type-II JAK inhibitor, CHZ-868. Using computational modeling, we postulate thatJAK2p.G993A enabled JAK2 activation in the presence of drug binding through a unique resistance mechanism that modulates the mobility of the conserved JAK2 activation loop. This study highlights the importance of monitoring mutation emergence and may inform future drug design and the development of therapeutic strategies for this high-risk patient cohort.

28 July 2020 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
MFMichelle O. Forgione
Michelle O. Forgione
Barbara McClureBarbara McClure
Barbara McClure
DYDavid T. Yeung
David T. Yeung
Laura EadieLaura Eadie
Laura Eadie
Deborah L WhiteDeborah L White
Deborah L White

2 December 2021 in Oncogene
Verified
Journal Article
Closed access
PDF file
Elyse C. PageElyse C. Page
Elyse C. Page
SHSusan Heatley
Susan Heatley
LELaura N. Eadie
Laura N. Eadie
Barbara McClureBarbara McClure
Barbara McClure
CBCharles E. de Bock
Charles E. de Bock
Deborah L WhiteDeborah L White
Deborah L White

29 August 2024 in Blood
Verified
Journal Article
Closed access
PDF file
Laura EadieLaura Eadie
Laura Eadie
ELElias Lagonik
Elias Lagonik
Elyse C. PageElyse C. Page
Elyse C. Page
CSCaitlin E. Schutz
Caitlin E. Schutz
SHSusan Heatley
Susan Heatley
Deborah L WhiteDeborah L White
Deborah L White
High-risk Ph-like ALL includes genomic rearrangement of the ABL1 and ABL2 genes (collectively ABL-rearranged, ABLr), and novel treatments are required. For High-risk Ph-like ALL includes genomic rearrangement of the ABL1 and ABL2 genes (collectively ABL-rearranged, ABLr), and novel treatments are required. For

12 December 2021 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
Barbara McClureBarbara McClure
Barbara McClure
MPManika Pal
Manika Pal
SHSusan Heatley
Susan Heatley
JRJacqueline Rehn
Jacqueline Rehn
CSCaitlin Schutz
Caitlin Schutz
Deborah L WhiteDeborah L White
Deborah L White
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

1 April 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
KYKwok Ho Yip
Kwok Ho Yip
DMDuncan McKenzie
Duncan McKenzie
HRHayley S. Ramshaw
Hayley S. Ramshaw
JCJessica Chao
Jessica Chao
Barbara McClureBarbara McClure
Barbara McClure
DTDamon J. Tumes
Damon J. Tumes